Reference number : 236-2013-2014-Q1-00052, amendment number : , agreement type : G, recipient legal name : ESSEBAG, Vidal, recipient country : CA, recipient province : QC, recipient city : Montreal, recipient postal code : H3A 2T5, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 180000.0, agreement start date : 2013-07-01, agreement end date : 2016-06-30, description english : BRUISE CONTROL-2: A randomized controlled trial to investigate whether a strategy of Continued versus Interrupted Dabigatran at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events, leads to a reduction in the incidence of clinically significant hematoma, description french : BRUISE CONTROL-2: A randomized controlled trial to investigate whether a strategy of Continued versus Interrupted Dabigatran at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events, leads to a reduction in the incidence of clinically significant hematoma, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2013-14 to 2016-17), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2013-14 à 2016-17), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada